FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2974169907> ?p ?o ?g. }

• W2974169907 endingPage "e0221994" @default.
• W2974169907 startingPage "e0221994" @default.
• W2974169907 abstract "Second-generation mammalian target of rapamycin (mTOR) inhibitors such as CC-223 may have theoretical advantages over first-generation drugs by inhibiting TOR kinase in mTOR complex 1 (mTORC1) and 2 (mTORC2), potentially improving clinical efficacy for well-differentiated neuroendocrine tumors (NET).Enrolled patients had metastatic, well-differentiated NET of non-pancreatic gastrointestinal or unknown origin, with/without carcinoid symptoms, had failed ≥1 systemic chemotherapy, and were taking a somatostatin analog (SSA). Oral once-daily CC-223 was administered in 28-day cycles starting at 45 mg (n = 24), with a subsequent cohort starting at 30 mg (n = 23). Objectives were to evaluate tolerability, preliminary efficacy, and pharmacokinetic and biomarker profiles of CC-223. Forty-seven patients completed the study, with mean treatment duration of 378 days and mean dose of 26 mg; 26% of patients remained on the starting dose. Most frequent grade ≥3 toxicities were diarrhea (38%), fatigue (21%), and stomatitis (11%). By investigator, 3 of 41 evaluable patients (7%) showed partial response (PR) and 34 (83%) had stable disease (SD) for a disease control rate (DCR) of 90% (95% confidence interval [CI] 76.9–97.3%). Duration of PR was 125–401 days; median SD duration was 297 days (min–max, 50–1519 days). Median progression-free survival was 19.5 months (95% CI 10.4–28.5 months). Carcinoid symptoms of flushing, diarrhea, or both improved in 50%, 41%, and 39% of affected patients, respectively. For the first time, this study describes that a second-generation mTOR pathway inhibitor can result in highly durable tumor regression and control of NET carcinoid symptoms. The manageable safety profile, high DCR, and durable response, coupled with reduction in carcinoid symptoms refractory to SSA, make CC-223 a promising agent for further development." @default.
• W2974169907 created "2019-09-26" @default.
• W2974169907 creator A5000961519 @default.
• W2974169907 creator A5002142386 @default.
• W2974169907 creator A5021719278 @default.
• W2974169907 creator A5028472820 @default.
• W2974169907 creator A5028833538 @default.
• W2974169907 creator A5043646929 @default.
• W2974169907 creator A5047069710 @default.
• W2974169907 creator A5049422612 @default.
• W2974169907 creator A5052765751 @default.
• W2974169907 creator A5055054082 @default.
• W2974169907 creator A5060350068 @default.
• W2974169907 creator A5065423718 @default.
• W2974169907 creator A5089084992 @default.
• W2974169907 date "2019-09-17" @default.
• W2974169907 modified "2023-10-18" @default.
• W2974169907 title "A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms" @default.
• W2974169907 cites W1605431033 @default.
• W2974169907 cites W1952574181 @default.
• W2974169907 cites W2002870649 @default.
• W2974169907 cites W2019607817 @default.
• W2974169907 cites W2100639001 @default.
• W2974169907 cites W2115686439 @default.
• W2974169907 cites W2146706890 @default.
• W2974169907 cites W2149214723 @default.
• W2974169907 cites W2209368665 @default.
• W2974169907 cites W2230497973 @default.
• W2974169907 cites W2329623393 @default.
• W2974169907 cites W2394944900 @default.
• W2974169907 cites W2481215053 @default.
• W2974169907 cites W2514906610 @default.
• W2974169907 cites W2560213035 @default.
• W2974169907 cites W2600107601 @default.
• W2974169907 cites W2753741557 @default.
• W2974169907 cites W4230704549 @default.
• W2974169907 doi "https://doi.org/10.1371/journal.pone.0221994" @default.
• W2974169907 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6748410" @default.
• W2974169907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31527867" @default.
• W2974169907 hasPublicationYear "2019" @default.
• W2974169907 type Work @default.
• W2974169907 sameAs 2974169907 @default.
• W2974169907 citedByCount "23" @default.
• W2974169907 countsByYear W29741699072019 @default.
• W2974169907 countsByYear W29741699072020 @default.
• W2974169907 countsByYear W29741699072021 @default.
• W2974169907 countsByYear W29741699072022 @default.
• W2974169907 countsByYear W29741699072023 @default.
• W2974169907 crossrefType "journal-article" @default.
• W2974169907 hasAuthorship W2974169907A5000961519 @default.
• W2974169907 hasAuthorship W2974169907A5002142386 @default.
• W2974169907 hasAuthorship W2974169907A5021719278 @default.
• W2974169907 hasAuthorship W2974169907A5028472820 @default.
• W2974169907 hasAuthorship W2974169907A5028833538 @default.
• W2974169907 hasAuthorship W2974169907A5043646929 @default.
• W2974169907 hasAuthorship W2974169907A5047069710 @default.
• W2974169907 hasAuthorship W2974169907A5049422612 @default.
• W2974169907 hasAuthorship W2974169907A5052765751 @default.
• W2974169907 hasAuthorship W2974169907A5055054082 @default.
• W2974169907 hasAuthorship W2974169907A5060350068 @default.
• W2974169907 hasAuthorship W2974169907A5065423718 @default.
• W2974169907 hasAuthorship W2974169907A5089084992 @default.
• W2974169907 hasBestOaLocation W29741699071 @default.
• W2974169907 hasConcept C126322002 @default.
• W2974169907 hasConcept C190283241 @default.
• W2974169907 hasConcept C197934379 @default.
• W2974169907 hasConcept C2776694085 @default.
• W2974169907 hasConcept C2778375690 @default.
• W2974169907 hasConcept C2778822529 @default.
• W2974169907 hasConcept C2779066768 @default.
• W2974169907 hasConcept C2779802037 @default.
• W2974169907 hasConcept C2779984678 @default.
• W2974169907 hasConcept C2781151469 @default.
• W2974169907 hasConcept C55493867 @default.
• W2974169907 hasConcept C71924100 @default.
• W2974169907 hasConcept C86554907 @default.
• W2974169907 hasConcept C86803240 @default.
• W2974169907 hasConcept C90924648 @default.
• W2974169907 hasConcept C98490376 @default.
• W2974169907 hasConceptScore W2974169907C126322002 @default.
• W2974169907 hasConceptScore W2974169907C190283241 @default.
• W2974169907 hasConceptScore W2974169907C197934379 @default.
• W2974169907 hasConceptScore W2974169907C2776694085 @default.
• W2974169907 hasConceptScore W2974169907C2778375690 @default.
• W2974169907 hasConceptScore W2974169907C2778822529 @default.
• W2974169907 hasConceptScore W2974169907C2779066768 @default.
• W2974169907 hasConceptScore W2974169907C2779802037 @default.
• W2974169907 hasConceptScore W2974169907C2779984678 @default.
• W2974169907 hasConceptScore W2974169907C2781151469 @default.
• W2974169907 hasConceptScore W2974169907C55493867 @default.
• W2974169907 hasConceptScore W2974169907C71924100 @default.
• W2974169907 hasConceptScore W2974169907C86554907 @default.
• W2974169907 hasConceptScore W2974169907C86803240 @default.
• W2974169907 hasConceptScore W2974169907C90924648 @default.
• W2974169907 hasConceptScore W2974169907C98490376 @default.
• W2974169907 hasFunder F4320309086 @default.
• W2974169907 hasIssue "9" @default.
• W2974169907 hasLocation W29741699071 @default.

• next